Antibacterial activity of phytochemicals isolated from Erythrina zeyheri against vancomycin-resistant enterococci and their combinations with vancomycin

被引:32
|
作者
Sato, M
Tanaka, H
Oh-Uchi, T
Fukai, T
Etoh, H
Yamaguchi, R
机构
[1] Asahi Univ, Sch Dent, Dept Oral Pathol, Gifu 5010296, Japan
[2] Meijo Univ, Fac Pharm, Dept Nat Prod Chem, Tempaku Ku, Nagoya, Aichi 4688503, Japan
[3] Toho Univ, Sch Pharmaceut Sci, Chiba 2748510, Japan
[4] Shizuoka Univ, Fac Agr, Lab Marine Biochem Sci, Shizuoka 4228529, Japan
[5] Asahi Univ, Sch Dent, Inst Radioisotope, Gifu 5010296, Japan
关键词
VRE; MRSA; erybraedin A; eryzerin C; vancomycin; FIC index;
D O I
10.1002/ptr.1556
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Six phytochemicals were isolated from the roots of Eiythrina zeyheri (Leguminosae) by repeated silica gel column chromatography using various eluting solvents. Extensive spectroscopic studies revealed that all were isoflavonoids. The antibacterial activity of the six compounds against vancomycin-resistant enterococci (VRE) was estimated by determining the minimum inhibitory concentration (MIC). Of the six isoflavonoids, erybraedin A ((6aR, 11aR)-3,9-dihydroxy-4,10-di(gamma,gamma-dimethylallyl)pterocarpan) exhibited the highest growth inhibitory potency against VRE with an MIC value of 1.56-3.13 mug/mL, followed by eryzerin C ((3R)-7,2',4'-trihydroxy-6,8-di(gamma,gamma-dimethylailyl)isoflavan) (MIC 6.25 mug/mL). These compounds also inhibited the growth of methicillin-resistant Staphylococcus aureus (MRSA) at 3.13-6.25 mug/mL. The antibacterial effects of the two compounds against VRE and MRSA were based on bacteriostatic action. When erybraedin A or eryzerin C was combined with vancomycin, the fractional inhibitory concentration (FIC) index against VRE ranged from 0.5306 to 1.0 and from 0.5153 to 0.75, respectively. The combinations also showed FIC indices of 0.6125-1.0 against MRSA. The results indicate that, depending on the case, both compounds act either synergistically or additively with vancomycin against VRE and MRSA. Erybraedin A and eryzerin C show evidence of being potent phytotherapeutic agents against infections caused by VRE and MRSA. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:906 / 910
页数:5
相关论文
共 50 条
  • [1] Novel vancomycin dimers with activity against vancomycin-resistant enterococci
    Sundram, UN
    Griffin, JH
    Nicas, TI
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1996, 118 (51) : 13107 - 13108
  • [2] Antibacterial activity of calozeyloxanthone isolated from Calophyllum species against vancomycin-resistant Enterococci (VRE) and synergism with antibiotics
    Sakagami, Y
    Kajimura, K
    Wijesinghe, WMNM
    Dharmaratne, HRW
    PLANTA MEDICA, 2002, 68 (06) : 541 - 543
  • [3] Cytotoxic Activity of Vancomycin-Resistant Enterococci Isolated from Hospitalised Patients
    Szczuka, Ewa
    Rolnicka, Dominika
    Wesolowska, Maria
    PATHOGENS, 2024, 13 (10):
  • [4] Vancomycin-resistant enterococci isolated from animals and food
    Robredo, B
    Singh, KV
    Baquero, F
    Murray, BE
    Torres, C
    INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, 2000, 54 (03) : 197 - 204
  • [5] Vancomycin-resistant enterococci
    Palmer, SM
    Rybak, MJ
    PHARMACOTHERAPY, 1996, 16 (05): : 819 - 829
  • [6] Vancomycin-resistant enterococci
    Looke, D
    NEPHROLOGY, 2002, 7 : S67 - S68
  • [7] VANCOMYCIN-RESISTANT ENTEROCOCCI
    HYMAN, GF
    JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 1995, 21 (06): : 599 - 600
  • [8] Vancomycin-resistant enterococci
    Murray, BE
    AMERICAN JOURNAL OF MEDICINE, 1997, 102 (03): : 284 - 293
  • [9] Vancomycin-resistant enterococci
    Moellering, RC
    CLINICAL INFECTIOUS DISEASES, 1998, 26 (05) : 1196 - 1199
  • [10] Vancomycin-resistant enterococci
    Cetinkaya, Y
    Falk, P
    Mayhall, CG
    CLINICAL MICROBIOLOGY REVIEWS, 2000, 13 (04) : 686 - +